Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-26). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. 002317.SZ files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.52% | 30.00% | Pass |
| Interest-bearing investments | 5.00% | 30.00% | Pass |
| Non-permissible income | 0.35% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 6.48% | 33.00% | Pass |
| Interest-bearing investments | 21.23% | 33.00% | Pass |
| Non-liquid assets | 67.60% | at least 20.00% | Pass |
| Non-permissible income | 0.35% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 6.48% | 33.33% | Pass |
| Cash + interest-bearing securities | 21.23% | 33.33% | Pass |
| Accounts receivable | 32.40% | 33.33% | Pass |
| Non-permissible income | 0.35% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 6.48% | 33.33% | Pass |
| Cash + interest-bearing securities | 21.23% | 33.33% | Pass |
| Accounts receivable | 32.40% | 50.00% | Pass |
| Non-permissible income | 0.35% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 2.12% | 33.00% | Pass |
| Cash + interest-bearing securities | 6.95% | 33.00% | Pass |
| Accounts receivable | 3.66% | 33.00% | Pass |
| Non-permissible income | 0.35% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 2.26% | 33.00% | Pass |
| Cash + interest-bearing securities | 7.41% | 49.00% | Pass |
| Accounts receivable | 3.90% | 49.00% | Pass |
| Non-permissible income | 0.35% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 2.26% | 33.33% | Pass |
| Cash + interest-bearing securities | 7.41% | 33.33% | Pass |
| Accounts receivable | 11.30% | 49.00% | Pass |
| Non-permissible income | 0.35% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 41.20 | NEUTRAL |
| Stochastic %K (14) | 26.35 | NEUTRAL |
| CCI (20) | -88.33 | NEUTRAL |
| Williams %R (14) | -73.65 | NEUTRAL |
| MACD (12,26,9) | -0.08 | SELL |
| ROC (10) | -7.20 | SELL |
| Momentum (10) | -1.88 | SELL |
| EMA (10) | 25.10 | SELL |
| SMA (10) | 24.98 | SELL |
| EMA (20) | 25.62 | SELL |
| SMA (20) | 25.81 | SELL |
| EMA (30) | 25.90 | SELL |
| SMA (30) | 26.43 | SELL |
| EMA (50) | 25.83 | SELL |
| SMA (50) | 27.08 | SELL |
| EMA (100) | 24.69 | SELL |
| SMA (100) | 24.50 | SELL |
| EMA (200) | 22.67 | BUY |
| SMA (200) | 22.22 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - Specialty & Generic
Guangdong Zhongsheng Pharmaceutical Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China. The company offers onradir, Leretevir, compound danshen, Cefixime Dispersible, Pyrazinamide, Ethamibutanol Hydrochloride, Ribavirin, loratadine, and isoniazid tablets; compound thromboplastin series, Zhong Sheng Wan series, and heat-clearing and dampness-removing granules products; NaoShuanTong, Cefadroxil, Rifampicin, and omeprazole enteric-coated capsules; carbocysteine, Ambroxol Hydrochloride, and Clomastine fumarate oral solutions; sucralfate oral suspension; reba pat film; and Azalastine Hydrochloride, Praprofen, Diquafosol Sodium, and Cyclosporine eye drops. It also focuses on the fields of respiratory antiviral, ophthalmology, cardiovascular and cerebrovascular endocrinology, anti-infection, digestion, and anti-allergy. Guangdong Zhongsheng Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Dongguan, China.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.